Progyny launches pregnancy, postpartum, and menopause programs for global employers, enhancing women’s health support starting January 1, 2026.
Quiver AI Summary
Progyny, Inc. has announced the launch of new programs focused on pregnancy, postpartum, and menopause, set to be available to global employers starting January 1, 2026. These initiatives enhance the company's existing fertility and family building services, addressing critical health needs for women at various life stages. Acknowledging the significant drop in employment due to menopause symptoms, Progyny aims to provide localized expertise and comprehensive care tailored to each country’s regulations and cultural contexts. Their offerings include personalized consultations, curated educational resources, and navigator support for necessary local care, ensuring a holistic approach to women's health in the workforce. Progyny's goal is to unify women’s health solutions for global companies while aiding productivity and retention, contributing to a potential $1 trillion addition to the global economy by 2040 through improved women’s health.
Potential Positives
- Progyny is launching pregnancy, postpartum, and menopause programs for global employers, expanding its suite of women's health and family building solutions, effective January 1, 2026.
- The new programs address critical unmet needs in women's health, as highlighted by research indicating that 1 in 10 working women have left jobs due to menopause symptoms, providing a compelling business case for employers to adopt these offerings.
- Progyny’s platform is tailored for global markets, enhancing its ability to support employees with localized, country-specific expertise, which can be crucial for the diverse workforce of multinational employers.
- The company has been recognized with multiple accolades, such as being listed as a TIME100 Most Influential Company and a CNBC Disruptor 50, underscoring its leadership in the industry and enhancing its brand credibility among potential clients.
Potential Negatives
- The launch of new programs may indicate a response to significant unmet needs in women's health, suggesting the company previously lacked adequate offerings in these areas.
- The press release emphasizes a gap in employer offerings regarding support for women, which could imply a competitive weakness or slow adaptation to market demands.
- Despite the announcement of new programs, it remains unclear how effectively these services will be integrated and received in diverse global markets, raising concerns about execution and impact.
FAQ
What new programs is Progyny launching for global employers?
Progyny is launching pregnancy, postpartum, and menopause programs for global employers starting January 1, 2026.
How do Progyny’s new offerings benefit working women?
The offerings provide specialized care for women at pivotal life stages, supporting health, productivity, and job retention.
What is unique about Progyny’s approach to women’s health?
Progyny combines global expertise with localized support, ensuring personalized care that aligns with country-specific needs and regulations.
How does Progyny address the challenges faced by employees during pregnancy and menopause?
Progyny offers personalized consultations, curated resources, and country-specific navigator support to help employees navigate their unique challenges.
Why is it important for employers to focus on women's health solutions?
Focusing on women's health can improve employee retention and productivity, with studies suggesting significant economic benefits for employers.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PGNY Insider Trading Activity
$PGNY insiders have traded $PGNY stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $PGNY stock by insiders over the last 6 months:
- ALLISON SWARTZ (EVP, GC) has made 0 purchases and 2 sales selling 2,997 shares for an estimated $69,152.
- CHERYL SCOTT sold 2,675 shares for an estimated $59,037
- KEVIN K GORDON sold 2,500 shares for an estimated $55,087
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PGNY Hedge Fund Activity
We have seen 154 institutional investors add shares of $PGNY stock to their portfolio, and 145 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- THRIVENT FINANCIAL FOR LUTHERANS removed 3,342,347 shares (-98.3%) from their portfolio in Q2 2025, for an estimated $73,531,634
- BLACKROCK, INC. added 1,813,119 shares (+14.2%) to their portfolio in Q2 2025, for an estimated $39,888,618
- VANGUARD GROUP INC added 1,252,671 shares (+14.5%) to their portfolio in Q2 2025, for an estimated $27,558,762
- MILLENNIUM MANAGEMENT LLC removed 876,142 shares (-67.2%) from their portfolio in Q2 2025, for an estimated $19,275,124
- CITADEL ADVISORS LLC removed 739,200 shares (-69.3%) from their portfolio in Q2 2025, for an estimated $16,262,400
- RENAISSANCE TECHNOLOGIES LLC added 727,800 shares (+inf%) to their portfolio in Q2 2025, for an estimated $16,011,600
- FMR LLC added 605,082 shares (+14.7%) to their portfolio in Q2 2025, for an estimated $13,311,804
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PGNY Analyst Ratings
Wall Street analysts have issued reports on $PGNY in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Cantor Fitzgerald issued a "Overweight" rating on 08/08/2025
- Leerink Partners issued a "Outperform" rating on 07/08/2025
To track analyst ratings and price targets for $PGNY, check out Quiver Quantitative's $PGNY forecast page.
$PGNY Price Targets
Multiple analysts have issued price targets for $PGNY recently. We have seen 5 analysts offer price targets for $PGNY in the last 6 months, with a median target of $27.0.
Here are some recent targets:
- Anne Samuel from JP Morgan set a target price of $25.0 on 08/26/2025
- Richard Close from Canaccord Genuity set a target price of $23.0 on 08/20/2025
- Sarah James from Cantor Fitzgerald set a target price of $28.0 on 08/08/2025
- Jailendra Singh from Truist Securities set a target price of $27.0 on 07/17/2025
- Michael Cherny from Leerink Partners set a target price of $28.0 on 07/08/2025
Full Release
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc . (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced the launch of its pregnancy, postpartum, and menopause programs for global employers, available starting January 1, 2026. These offerings complement the availability of the company’s existing and marketing-leading global fertility and family building offering, providing multi-national employers with a continuum of integrated services. Progyny’s localized global expertise and member-first experience are supporting unmet needs across pivotal women’s and family life stages.
Global employers are recognizing the need to offer specialized care for women in the workforce, as supported by a UK study that showed 1 in 10 working women left a job due to menopause symptoms. Progyny's platform was purpose-built for global markets, supporting members in their country-specific environment, helping them with expert support through stages of pregnancy, postpartum, menopause, and midlife to optimize health, productivity, and retention. Employees uniquely have access to:
- Personalized consultations and guided programs with Global Care Advocates, with maternal health, menopause, and mental health expertise.
- A curated knowledge center for evidence-based education on symptoms, work-life balance, relationships, emotional well-being, and mental health.
- Country-specific navigator support for local care, regulations, policies, and protections.
- A GDPR-compliant platform and benefit administration tailored to meet the unique needs of different regions.
“We’ve done extensive research and heard from employers that a clear gap exists – they need local market expertise and real partnership for their employees. Progyny’s global offerings combine our recognized focus on clinical expertise with localized guidance, helping members find and connect to the right care at the right time, wherever our members live,” says Jenny Saft, General Manager of Global Markets, Progyny. “For global employers, this means a unified women’s health solution that provides expert-led human support while simplifying benefit administration across regions.”
According to a McKinsey study , closing gaps in women’s health globally could add $1 trillion to the global economy by 2040. By combining country-specific expertise with global scale, Progyny is uniquely meeting employer needs with highly sought, specialized knowledge to support employees’ needs including assistance comprehending public coverage, understanding referral requirements, and navigating leave rules. This unique approach delivers meaningful, cohesive guidance designed to support language and cultural needs.
The Progyny Global experience is multilingual, covering the most common languages spoken in more than 127 countries with the capabilities to support employees in every country around the world.
For more information on Progyny Global, visit https://progynyglobal.com/
About Progyny
Progyny (Nasdaq: PGNY) is a global leader in women’s health and family building solutions, trusted by the nation’s leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients, and physicians.
Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.
Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.
For Further Information, Please Contact:
Media:
Alexis Ford
[email protected]
Investors:
James Hart
[email protected]
